-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $17

Benzinga·11/10/2025 16:08:24
Listen to the news
RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $19 to $17.